Patrick Daly

DocwireNews

Co-first authors of a study published in Advances in Rheumatology, Alisson Pugliesi and Amanda Borges de Oliveira, led a network meta-analysis to compare the efficacy of rituximab, tocilizumab, and abatacept in patients with rheumatoid arthritis who developed resistance to methotrexate or tumor necrosis factor inhibitor (TNFi) treatment.
Rituximab, abatacept, and tocilizumab all reportedly achieved similar rates of <a href="https://www.docwirenews.com/post/acr-guidelines-recommend-an-integrated-approach-to-managing-rheumatoid-arthritis">American College of Rheumatology</a> ≥70% disease activity improvement (ACR70) outcomes at 6 months; however, authors noted there was a high degree of heterogeneity between the included trials.
<h3>Best Rheumatoid Arthritis Treatments for Refractory Patients</h3>
The researchers attempted to mathematically equalize imbalanced factors between the randomized, controlled trials and compared efficacy again using multivariate metaregressions. Based on this analysis, they estimated abatacept potentially improved the odds of achieving ACR70 responses by 2.2-fold compared with tocilizumab.
Analysts identified 19 randomized, controlled trials on biologic disease-modifying antirheumatic drugs that enrolled a total of 7835 patients with rheumatoid arthritis refractory to <a href="https://www.docwirenews.com/post/golimumab-with-or-without-methotrexate-in-rheumatoid-arthritis">methotrexate</a> or TNFi therapy. The mean study duration was 1.2 years.
According to the report, the 3 critically imbalanced factors between rituximab, abatacept, and tocilizumab studies were baseline health assessment questionnaire score, study duration, and TNFi treatment frequency in the control group.
After adjusting for these factors, Pugliesi, Borges de Oliveira, and colleagues stated the heterogeneity between the studies was reduced (I2=24%) and their model&#8217;s power was increased (R2=85%).
This model found <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125118s171lbl.pdf" target="_blank" rel="noopener">abatacept</a> had a risk ratio of 2.217 for achieving ACR70 compared with tocilizumab (95% CI, 1.554-3.161; P&lt;.001) and a risk ratio of 1.773 compared with rituximab (95% CI, 0.113-10.210; P&lt;.765).
Ultimately, the study&#8217;s authors suggested abatacept or rituximab should be evaluated before tocilizumab in patients with refractory rheumatoid arthritis, though they acknowledged that &#8220;novel head-to-head clinical trials are still needed to confirm these findings.&#8221;
More Research on <a href="https://www.docwirenews.com/page/rheumatology">Rheumatology</a> and <a href="https://www.docwirenews.com/page/rheumatoid-arthritis">Rheumatoid Arthritis</a>

Rob Dillard

ChatGPT Can Improve Black Women's Understanding of HIV Prevention

Study Identifies Key Mechanisms of a Common Complication of Crohn Disease

Gastroenterology

Emily Menendez

Lenvatinib Plus Tislelizumab Offers Antitumor Activity for First-line Treatment of uHCC

Unresectable HCC

Latest News

Abatacept Potentially Optimal for Refractory Rheumatoid Arthritis

Rheumatoid Arthritis

Abatacept improved outcomes for rheumatoid arthritis refractory to methotrexate or TNFi versus rituximab or tocilizumab treatment, meta-analysis suggests.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Diabetes

Neurology

Rheumatology

Pulmonology

Ophthalmology

Infectious Diseases

Health and Wellness

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Fellow on Call

Healthcare Unfiltered

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Career Center

Expert Interviews

Subscribe